AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25779892 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT) for 12 weeks
Number of subjects: 31
Study 25779892 — intervention group
Group type: COMPARATOR
Intervention: Control Group (no intervention)
Number of subjects: 31
Study 23980043 — intervention group
Group type: EXPERIMENTAL
Intervention: Early oral feeding with enteral nutrition
Number of subjects: 48
Study 23980043 — intervention group
Group type: COMPARATOR
Intervention: Conventional postoperative care protocol
Number of subjects: 48
Study 21366964 — intervention group
Group type: EXPERIMENTAL
Intervention: MSM+EDTA lotion
Number of subjects: 0
Study 21366964 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 0
Study 21366964 — intervention group
Group type: EXPERIMENTAL
Intervention: MSM alone
Number of subjects: 0
Study 19644033 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal voluntary isometric contractions (MVICs)
Number of subjects: 16
Study 19644033 — intervention group
Group type: COMPARATOR
Intervention: Static plantar flexor stretches
Number of subjects: 16
Study 17684963 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin and iron preparations
Number of subjects: 189
Study 17684963 — intervention group
Group type: COMPARATOR
Intervention: Untreated anemia (Control group)
Number of subjects: 189
Study 17684963 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of epoetin and parenteral iron preparations
Number of subjects: 189
Study 15173493 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 400 microg/day
Number of subjects: 63
Study 15173493 — intervention group
Group type: COMPARATOR
Intervention: Nedocromil 16 mg/day
Number of subjects: 63
Study 15173493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 11705138 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9646297 — intervention group
Group type: EXPERIMENTAL
Intervention: disease-specific (reduced-carbohydrate, modified-fat) formula
Number of subjects: 30
Study 9646297 — intervention group
Group type: COMPARATOR
Intervention: standard high-carbohydrate formula
Number of subjects: 30
Study 8572070 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin eardrops
Number of subjects: 56
Study 8572070 — intervention group
Group type: COMPARATOR
Intervention: Augmentin
Number of subjects: 56
Study 6242073 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied clindamycin phosphate 1% b.i.d.
Number of subjects: 87
Study 6242073 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tetracyclines 500 mg b.i.d.
Number of subjects: 87
Study 6242073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 31524347 — intervention group
Group type: EXPERIMENTAL
Intervention: Tretinoin 0.05% lotion
Number of subjects: 69
Study 31524347 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 69
Study 29617739 — intervention group
Group type: EXPERIMENTAL
Intervention: RBX2660 (2 doses)
Number of subjects: 100
Study 29617739 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 doses)
Number of subjects: 100
Study 29617739 — intervention group
Group type: EXPERIMENTAL
Intervention: RBX2660 (1 dose) followed by Placebo (1 dose)
Number of subjects: 100
Study 29617739 — intervention group
Group type: EXPERIMENTAL
Intervention: RBX2660 (1 dose)
Number of subjects: 100
Study 27046798 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose antithrombin (3000 IU/daily)
Number of subjects: 38
Study 27046798 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1% glycine)
Number of subjects: 38
Study 24520915 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioners (GPs) faxed invitations with telephone follow-up
Number of subjects: 3893
Study 24520915 — intervention group
Group type: EXPERIMENTAL
Intervention: Older people invited through reply-paid cards with telephone follow-up
Number of subjects: 3893
Study 24520915 — intervention group
Group type: EXPERIMENTAL
Intervention: GP's length of time at the practice and training in New Zealand
Number of subjects: 3893
Study 22185431 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.62% testosterone gel (81 mg testosterone) applied once daily for 7 days with washing at 2 hours post-dose
Number of subjects: 24
Study 22185431 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.62% testosterone gel (81 mg testosterone) applied once daily for 7 days with washing at 6 hours post-dose
Number of subjects: 24
Study 22185431 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.62% testosterone gel (81 mg testosterone) applied once daily for 7 days with washing at 10 hours post-dose
Number of subjects: 24
Study 22185431 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.62% testosterone gel (81 mg testosterone) applied once daily for 7 days with no washing
Number of subjects: 24
Study 20559225 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycloferon
Number of subjects: 61
Study 20559225 — intervention group
Group type: COMPARATOR
Intervention: Conventional drug therapy
Number of subjects: 61
Study 17912169 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow stem cell therapy (BM-derived cells injected into infarcted hearts)
Number of subjects: 0
Study 17912169 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group in initial randomized trials)
Number of subjects: 0
Study 17299062 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride (0.5 mg)
Number of subjects: 99
Study 17299062 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg)
Number of subjects: 99
Study 17299062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 14760334 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week progressive home walking exercise program (n = 42)
Number of subjects: 79
Study 14760334 — intervention group
Group type: COMPARATOR
Intervention: Usual activity control group (n = 37)
Number of subjects: 79
Study 10798473 — intervention group
Group type: EXPERIMENTAL
Intervention: Abilities-focused program of morning care
Number of subjects: 84
Study 10798473 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 84
Study 8780347 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg gastric-delivery-system (GDS) iron supplement
Number of subjects: 0
Study 8780347 — intervention group
Group type: COMPARATOR
Intervention: 120 mg conventional (Con) iron supplement
Number of subjects: 0
Study 1622308 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support intervention
Number of subjects: 88
Study 1622308 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 88
Study 6503365 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 70
Study 6503365 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol
Number of subjects: 70
Study 30719455 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Care Model-based intervention
Number of subjects: 300
Study 28856398 — intervention group
Group type: EXPERIMENTAL
Intervention: Current use of SSRIs (last tablet noted ≤ 7 days before diagnosis)
Number of subjects: 9262
Study 28856398 — intervention group
Group type: EXPERIMENTAL
Intervention: Late use of SSRIs (last tablet noted ≥ 8 days before diagnosis)
Number of subjects: 9262
Study 28856398 — intervention group
Group type: COMPARATOR
Intervention: No use of SSRIs (never prescribed SSRIs)
Number of subjects: 9262
Study 26195460 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-lasting permethrin-impregnated clothing
Number of subjects: 0
Study 26195460 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (not wearing treated uniforms)
Number of subjects: 0
Study 23916987 — intervention group
Group type: EXPERIMENTAL
Intervention: S. Typhi ISP1820
Number of subjects: 60
Study 23916987 — intervention group
Group type: EXPERIMENTAL
Intervention: S. Typhi Ty2 RpoS(-)
Number of subjects: 60
Study 23916987 — intervention group
Group type: EXPERIMENTAL
Intervention: S. Typhi Ty2 RpoS(+)
Number of subjects: 60
Study 21175345 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiated eyes of 1-year-old rats exposed to 2 Gy of (56)Fe ions
Number of subjects: 2
Study 21175345 — intervention group
Group type: EXPERIMENTAL
Intervention: Older ovariectomized rats receiving exogenous estrogen treatment (17-β-estradiol)
Number of subjects: 2
Study 21175345 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiated eyes of young rats
Number of subjects: 2
Study 21175345 — intervention group
Group type: EXPERIMENTAL
Intervention: Modulation of estrogen status in 1-year-old animals (e.g., ovariectomy or continuous exposure to estrogen)
Number of subjects: 2
Study 18501444 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Exercise (CE)
Number of subjects: 52
Study 18501444 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval Exercise (IE)
Number of subjects: 52
Study 16704586 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-breath vital capacity technique
Number of subjects: 73
Study 16704586 — intervention group
Group type: COMPARATOR
Intervention: Tidal volume technique
Number of subjects: 73
Study 16704586 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 73
Study 15587771 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AA) plus etomidate group
Number of subjects: 22
Study 15587771 — intervention group
Group type: COMPARATOR
Intervention: Control group (etomidate only)
Number of subjects: 22
Study 11392363 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) at half dose
Number of subjects: 96
Study 9427453 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri (10^7 cfu)
Number of subjects: 66
Study 9427453 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri (10^10 cfu)
Number of subjects: 66
Study 9427453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 8276557 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (20 mg daily, starting 2 hours before surgery)
Number of subjects: 1122
Study 8276557 — intervention group
Group type: COMPARATOR
Intervention: Calcium heparin (2 doses of 0.2 ml daily, starting 2 hours before surgery)
Number of subjects: 1122
Study 8276557 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 1122
Study 8276557 — intervention group
Group type: COMPARATOR
Intervention: Calcium heparin
Number of subjects: 1122
Study 3524744 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular chloroquine diphosphate, 2.5 mg base/kg at 0, 1, 12, 13, 24, and 25 hours
Number of subjects: 0
Study 3524744 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous chloroquine diphosphate, 5 mg base/kg at 0, 12, and 24 hours
Number of subjects: 0
Study 3524744 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular chloroquine diphosphate
Number of subjects: 0
Study 3524744 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous chloroquine diphosphate
Number of subjects: 0
Study 28618198 — intervention group
Group type: EXPERIMENTAL
Intervention: IV paracetamol pre-emptive analgesia (15 mg/kg before treatment)
Number of subjects: 60
Study 28618198 — intervention group
Group type: COMPARATOR
Intervention: IV paracetamol preventive analgesia (15 mg/kg at the end of treatment)
Number of subjects: 60
Study 28618198 — intervention group
Group type: EXPERIMENTAL
Intervention: IV paracetamol pre-emptive analgesia
Number of subjects: 60
Study 27184343 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing plus biomarker feedback (SHSe feedback)
Number of subjects: 341
Study 27184343 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced-PAM (six asthma education/smoking cessation calls + repeat SHSe feedback)
Number of subjects: 341
Study 27184343 — intervention group
Group type: COMPARATOR
Intervention: PAM (six asthma education calls)
Number of subjects: 341
Study 27184343 — intervention group
Group type: EXPERIMENTAL
Intervention: Teachable Moment (TM) effect
Number of subjects: 341
Study 25306220 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised best practice ergonomic intervention plus 3×20 minute weekly, progressive neck/shoulder girdle exercise group sessions for 12 weeks.
Number of subjects: 640
Study 25306220 — intervention group
Group type: COMPARATOR
Intervention: Individualised best practice ergonomic intervention plus 1‐hour weekly health information sessions for 12 weeks.
Number of subjects: 640
Study 22430687 — intervention group
Group type: EXPERIMENTAL
Intervention: Freeze-dried dura mater allograft (experimental group)
Number of subjects: 12
Study 22430687 — intervention group
Group type: COMPARATOR
Intervention: Open debridement (control group)
Number of subjects: 12
Study 20547399 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV‐11
Number of subjects: 1111
Study 20547399 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 1111
Study 18938214 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromazepam 6 mg
Number of subjects: 39
Study 18938214 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromazepam 3 mg
Number of subjects: 39
Study 18938214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 15968010 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (control)
Number of subjects: 168
Study 12187458 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis threat group
Number of subjects: 36
Study 12187458 — intervention group
Group type: COMPARATOR
Intervention: Neutral test directions group
Number of subjects: 36
Study 9735969 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report version of the BASIS-32
Number of subjects: 120
Study 9735969 — intervention group
Group type: COMPARATOR
Intervention: Interview version of the BASIS-32
Number of subjects: 120
Study 9735969 — intervention group
Group type: EXPERIMENTAL
Intervention: Both self-report and interview versions of the BASIS-32
Number of subjects: 120
Study 7713242 — intervention group
Group type: EXPERIMENTAL
Intervention: Methazolamide 50 mg q.i.d. for 2 weeks
Number of subjects: 14
Study 7713242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 2655521 — intervention group
Group type: EXPERIMENTAL
Intervention: Intestinal decontamination (group 3) with neomycin, polymyxin E, and nalidixic acid
Number of subjects: 124
Study 2655521 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 2)
Number of subjects: 124
Study 2655521 — intervention group
Group type: EXPERIMENTAL
Intervention: No intervention (group 1)
Number of subjects: 124
Study 2655521 — intervention group
Group type: EXPERIMENTAL
Intervention: Intestinal decontamination (group 3)
Number of subjects: 124
Study 591936 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana extract calibrated to 0.3 mg/kg delta‐9‐tetrahydrocannabinol
Number of subjects: 16
Study 591936 — intervention group
Group type: EXPERIMENTAL
Intervention: Association‐overt rehearsal procedure
Number of subjects: 16
Study 591936 — intervention group
Group type: COMPARATOR
Intervention: Placebo conditions
Number of subjects: 16
Study 30658669 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 280
Study 30658669 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 280
Study 28662531 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal leg strength program (80-95% of 1-RM, 1-3 repetitions, 3-6 sets, 3-4 min rest between sets) performed twice a week for 10 weeks.
Number of subjects: 22
Study 28662531 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional strength training).
Number of subjects: 22
Study 25366615 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol 200 mg/day with enteral nutrition (EN) and parenteral nutrition (PN)
Number of subjects: 130
Study 25366615 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (control group)
Number of subjects: 130
Study 22837543 — intervention group
Group type: EXPERIMENTAL
Intervention: Buteyko breathing technique
Number of subjects: 120
Study 22837543 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranayama breathing technique
Number of subjects: 120
Study 22837543 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine pharmacological management)
Number of subjects: 120
Study 21431373 — intervention group
Group type: EXPERIMENTAL
Intervention: Single high‐dosage extracorporeal shockwave therapy (0.3 mJ/mm(2))
Number of subjects: 30
Study 21431373 — intervention group
Group type: COMPARATOR
Intervention: Two sessions of low‐dosage extracorporeal shockwave therapy (0.2 mJ/mm(2))
Number of subjects: 30
Study 19398066 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Frequency Group (2 times/week for 5 weeks)
Number of subjects: 30
Study 19398066 — intervention group
Group type: COMPARATOR
Intervention: High Frequency Group (5 times/week for 2 weeks)
Number of subjects: 30
Study 16691091 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy (MT; mainly spinal mobilization)
Number of subjects: 183
Study 16691091 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy (PT; mainly exercise therapy)
Number of subjects: 183
Study 16691091 — intervention group
Group type: COMPARATOR
Intervention: Continued care by the general practitioner (GP; analgesics, counseling and education)
Number of subjects: 183
Study 16691091 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy (MT)
Number of subjects: 183
Study 16691091 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy (PT)
Number of subjects: 183
Study 16691091 — intervention group
Group type: COMPARATOR
Intervention: Continued care by the general practitioner (GP)
Number of subjects: 183
Study 14586663 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-minute stationary cycle ergometry session at 65% of Vdot;O(2max)
Number of subjects: 0
Study 10670390 — intervention group
Group type: EXPERIMENTAL
Intervention: Care Planning Simulation System (CPSS)
Number of subjects: 108
Study 10670390 — intervention group
Group type: COMPARATOR
Intervention: Nutrition Care Planning Tutorial (NCPT)
Number of subjects: 108
Study 10670390 — intervention group
Group type: EXPERIMENTAL
Intervention: CPSS-I and NCPT-I groups (interns who started clinical rotations immediately after orientation)
Number of subjects: 108
Study 10670390 — intervention group
Group type: COMPARATOR
Intervention: CPSS-D and NCPT-D groups (interns who began their clinical rotations later)
Number of subjects: 108
Study 10670390 — intervention group
Group type: EXPERIMENTAL
Intervention: CPSS
Number of subjects: 108
Study 8974552 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual consultations with a family physician in his office (Group I)
Number of subjects: 135
Study 8974552 — intervention group
Group type: EXPERIMENTAL
Intervention: Group sessions with a physician and a dietician (Group II)
Number of subjects: 135
Study 8974552 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual consultations with a dietician (Group III)
Number of subjects: 135
Study 8974552 — intervention group
Group type: COMPARATOR
Intervention: Counseling (general outcome across all groups)
Number of subjects: 135
Study 1405268 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous large dose streptokinase
Number of subjects: 57
Study 1405268 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS score system
Number of subjects: 57
Study 3894494 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (Tagamet) 300 mg q.i.d.
Number of subjects: 38
Study 3894494 — intervention group
Group type: COMPARATOR
Intervention: Mylanta II 10 ml q.i.d.
Number of subjects: 38
Study 29017067 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine
Number of subjects: 3
Study 29017067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 28165762 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine extended-release (GXR) 1-6 mg daily
Number of subjects: 83
Study 28165762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 28165762 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine extended-release (GXR)
Number of subjects: 83
Study 26607762 — intervention group
Group type: EXPERIMENTAL
Intervention: Active recruitment (contacting eligible families directly)
Number of subjects: 194
Study 26607762 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive recruitment (informing the community through flyers, public events, media)
Number of subjects: 194
Study 26607762 — intervention group
Group type: COMPARATOR
Intervention: Media-led enquiries
Number of subjects: 194
Study 26607762 — intervention group
Group type: COMPARATOR
Intervention: Information seen at schools or GP surgeries
Number of subjects: 194
Study 23182965 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based intervention (HB)
Number of subjects: 99
Study 23182965 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention (CB)
Number of subjects: 99
Study 23182965 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 99
Study 21989306 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic version of the Faces Pain Scale-Revised (FPS-R)
Number of subjects: 202
Study 21989306 — intervention group
Group type: COMPARATOR
Intervention: Paper version of the Faces Pain Scale-Revised (FPS-R)
Number of subjects: 202
Study 21989306 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for the version of FPS-R
Number of subjects: 202
Study 18419443 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B inhalation (twice a week until neutrophil counts >300 cells/mm3)
Number of subjects: 271
Study 18419443 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhalation
Number of subjects: 271
Study 18419443 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B inhalation (on-treatment analysis)
Number of subjects: 271
Study 18419443 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhalation (on-treatment analysis)
Number of subjects: 271
Study 18419443 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B
Number of subjects: 271
Study 16850791 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer anthropometry monitoring
Number of subjects: 44
Study 16850791 — intervention group
Group type: EXPERIMENTAL
Intervention: Restoration treatment
Number of subjects: 44
Study 12949595 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial group intervention (6-week duration including health education, coping skills training, stress management, and psychological support)
Number of subjects: 50